<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475432</url>
  </required_header>
  <id_info>
    <org_study_id>TRS-009</org_study_id>
    <nct_id>NCT04475432</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis</brief_title>
  <acronym>Saturn-1</acronym>
  <official_title>Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarsus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarsus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop,&#xD;
      to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite&#xD;
      frequently found in human hair follicles. The hypothesis for the study is the proportion of&#xD;
      participants cured at Day 43 with treatment by TP-03, 0.25%, is greater than the proportion&#xD;
      cured by treatment with its vehicle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2b/3 study is a randomized, controlled, multicenter, double-masked, parallel trial&#xD;
      to compare the safety and efficacy of TP-03, 0.25%, to vehicle control for the treatment of&#xD;
      Demodex blepharitis. The primary objective of the study is to assess the safety and efficacy&#xD;
      of TP-03 compared to its vehicle from Day 1 to Day 43 in adult participants with mild to&#xD;
      severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon&#xD;
      collarettes. Safety will be determined by assessing adverse effects related to the treatment&#xD;
      as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp&#xD;
      biomicroscopy and dilated ophthalmoscopy findings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Actual">May 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active arm: TP-03 0.25%&#xD;
Control arm: Vehicle of TP-03</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment assignment will be unknown to the study participant, investigators and site staff performing study assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants cured based on their collarette score</measure>
    <time_frame>43 days</time_frame>
    <description>Cure is defined as the presence of no more than 2 collarettes on the upper eyelid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with their Demodex mites eradicated</measure>
    <time_frame>43 days</time_frame>
    <description>Mite eradication is defined as a mite density of 0 mites per lash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants cured based on a composite of collarette score and erythema cure</measure>
    <time_frame>43 days</time_frame>
    <description>Cure is defined as the presence of no more than 2 collarettes and the absence of erythema (age normal) of the upper eyelid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">421</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-03, 0.25%</intervention_name>
    <description>TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Lotilaner ophthalmic solution, 0.25%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-03 Vehicle</intervention_name>
    <description>Vehicle of TP-03 ophthalmic solution, administered twice a day</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Inactive control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing to sign the informed consent and deemed capable of complying with the&#xD;
             requirements of the study protocol&#xD;
&#xD;
          -  Meet all of the following criteria in at least one eye: Have more than 10 lashes with&#xD;
             collarettes present on the upper lid; have at least mild erythema of the upper eyelid&#xD;
             margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or&#xD;
             more mites per lash&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have used lid hygiene products within 14 days of Screening or unwilling to forego the&#xD;
             use of lid hygiene products during the study&#xD;
&#xD;
          -  Have worn contact lenses within 7 days of Screening or be unwilling to forego contact&#xD;
             lens wear during the study&#xD;
&#xD;
          -  Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be&#xD;
             unwilling to forego their use during the study&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wirta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornea and Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionary Eye Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cornea Associates, LLC</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washburn Research LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oculus Research, Inc at EyecareCenter</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Eye Clinic</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates, PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, P.A.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Demodex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

